Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sodium metaarsenite - Komipharm International

Next Previous
X
Search
Drug Profile

Sodium metaarsenite - Komipharm International

Alternative Names: KML 001; KOMINOX; PANAPHIX; PAX-1

Latest Information Update: 28 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Komipharm International
  • Developer Komipharm International; University of Maryland Greenbaum Cancer Center
  • Class Antineoplastics; Arsenicals
  • Mechanism of Action Gene expression modulators; Signal transduction pathway modulators; Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Biliary cancer; Cancer pain; Cholangiocarcinoma; Glioblastoma; Liver cancer; Lymphoma; Non-Hodgkin's lymphoma; Prostate cancer
  • Phase I Lung cancer; Solid tumours
  • No development reported Brain cancer; Non-small cell lung cancer

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in Brain-cancer in South Korea (PO)
  • 28 Sep 2022 Sodium metaarsenite is still in phase-I development in Lung-cancer in USA (PO) (Komipharm pipeline, September 2022)
  • 28 Sep 2022 Sodium metaarsenite is still in phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea (PO) (Komipharm pipeline, September 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top